Kazuki Fukuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kazuki Fukuma has a total of 248 co-authors. Here are the top co-authors by number of shared publications:
- Masafumi Ihara
Department of Neurology, National Cerebral and Cardiovascular Center, Osaka, Japan
21 shared publications - Tomotaka Tanaka
Department of Neurology, National Cerebral and Cardiovascular Center, Osaka, Japan
14 shared publications Kunihiro Nishimura
Department of Preventive Medicine and Epidemiology National Cerebral and Cardiovascular Center Osaka Japan
6 shared publicationsAkihiro Shimotake
Department of Neurology Kyoto University Graduate School of Medicine Kyoto Japan
5 shared publicationsAkio Ikeda
From the Department of Neurology (T.T., M.I., K.F.), National Cerebral and Cardiovascular Center, Osaka, Japan; Department of Neurology (N.K.M.), Yale University School of Medicine, New Haven, CT; Department of Clinical & Experimental Epilepsy (M.J.K.), UCL Queen Square Institute of Neurology, London, United Kingdom; Moscow Research and Clinical Center for Neuropsychiatry (A.G.), Pirogov Russian National Research Medical University, Russia; and Department of Epilepsy, Movement Disorders and...
5 shared publicationsKatsuya Kobayashi
Department of Neurology Kyoto University Graduate School of Medicine Kyoto Japan
5 shared publications
Latest Publications
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e047996
Prognostic Implications of Poststroke Aphasia: A Multicenter Cohort Study in Tertiary Hospitals
Background: Poststroke aphasia (PSA) may adversely affect recovery after ischemic stroke, but its association with functional decline and death remains unclear. We investigated the prognostic impact of PSA in survivors of stroke. Methods: This international observational cohort study included patients admitted to tertiary hospitals in Japan and South Korea within 7 days of ischemic stroke between 2011 and 2023. PSA was assessed using the language subscore of the National Institutes of Health Stroke Scale at discharge. Outcomes were worsening of the modified Rankin Scale score by ≥1 point and all‐cause death at 3 months in both cohorts and at 1 year in the Japanese cohort, using discharge as the index time point. Associations between PSA severity and outcomes were examined using multivariable models. Results: Among 9868 patients, 1651 (16.7%) had PSA, which independently predicted 3‐month worsening modified Rankin Scale score in Japan (odds ratio [OR], 2.52 [95% CI, 2.08–3.04]) and South Korea (OR, 1.68 [95% CI, 1.31–2.15]). PSA was associated with 3‐month death in Japan (OR, 3.47 [95% CI, 2.38–5.07]), while only global PSA predicted 3‐month death in South Korea (OR, 2.11 [95% CI, 1.28–3.47]). In Japan, PSA remained associated with 1‐year worsening modified Rankin Scale score (OR, 1.84 [95% CI, 1.49–2.26]) and death (OR, 2.63 [95% CI, 2.03–3.40]). Conclusions: PSA is independently associated with functional decline and death after ischemic stroke. Early recognition and targeted management of PSA may improve poststroke outcomes.
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e047996
Prognostic Implications of Poststroke Aphasia: A Multicenter Cohort Study in Tertiary Hospitals
Background: Poststroke aphasia (PSA) may adversely affect recovery after ischemic stroke, but its association with functional decline and death remains unclear. We investigated the prognostic impact of PSA in survivors of stroke. Methods: This international observational cohort study included patients admitted to tertiary hospitals in Japan and South Korea within 7 days of ischemic stroke between 2011 and 2023. PSA was assessed using the language subscore of the National Institutes of Health Stroke Scale at discharge. Outcomes were worsening of the modified Rankin Scale score by ≥1 point and all‐cause death at 3 months in both cohorts and at 1 year in the Japanese cohort, using discharge as the index time point. Associations between PSA severity and outcomes were examined using multivariable models. Results: Among 9868 patients, 1651 (16.7%) had PSA, which independently predicted 3‐month worsening modified Rankin Scale score in Japan (odds ratio [OR], 2.52 [95% CI, 2.08–3.04]) and South Korea (OR, 1.68 [95% CI, 1.31–2.15]). PSA was associated with 3‐month death in Japan (OR, 3.47 [95% CI, 2.38–5.07]), while only global PSA predicted 3‐month death in South Korea (OR, 2.11 [95% CI, 1.28–3.47]). In Japan, PSA remained associated with 1‐year worsening modified Rankin Scale score (OR, 1.84 [95% CI, 1.49–2.26]) and death (OR, 2.63 [95% CI, 2.03–3.40]). Conclusions: PSA is independently associated with functional decline and death after ischemic stroke. Early recognition and targeted management of PSA may improve poststroke outcomes.
- Open Access
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214647
Progressive Changes in Brain Morphology in People With Idiopathic Generalized Epilepsy
Idiopathic generalized epilepsy (IGE) is typically responsive to treatment, yet some people remain poorly controlled despite multiple antiseizure medication trials. Whether this subgroup shows progressive structural brain changes remains uncertain. We aimed to investigate whether people with poorly controlled chronic IGE exhibit progressive morphological brain alterations and how these differ from those in early-stage IGE. This longitudinal case-control neuroimaging study included 2 cohorts: an early-stage IGE group from West China Hospital (Chengdu, China) and a chronic IGE group from the National Hospital for Neurology and Neurosurgery (London, United Kingdom). Participants had a history of generalized seizures and no focal pathology. Matched healthy controls were drawn from 3 public imaging data sets. Participants underwent 2 high-resolution T1-weighted MRI scans at least 12 months apart. Cortical thickness and hippocampal and subcortical volumes were measured on paired scans. Longitudinal changes were assessed using linear mixed-effects models, correcting for age and interscan interval. Structural covariance analysis was conducted to examine inter-regional relationships over time, focusing on thalamo-cortical coupling. Forty-two people with early-stage IGE and 67 with chronic IGE were recruited from 2 separate epilepsy centers, and 109 matched controls were included. The early-stage IGE group showed progressive atrophy limited to the left putamen. Chronic IGE was associated with widespread cortical thinning, primarily in frontal and temporal regions, and thickening in posterior and occipital areas. Subcortical atrophy involves the putamen, thalamus, and pallidum. People with ongoing generalized tonic-clonic seizures showed thickening in the precentral gyrus and additional thinning in the frontal cortex and precuneus. Photosensitive IGE was associated with thickening in the lingual gyrus and occipital cortex. Valproate use was associated with attenuated structural changes in motor, visual, and subcortical regions. Increased structural covariance was observed between the left thalamus and left lingual gyrus in chronic IGE. Chronic IGE, particularly with persistent generalized tonic-clonic seizures or photosensitivity, is associated with more extensive progressive brain changes compared with matched controls. Valproate may have a protective association with these structural changes, although further validation is needed. Longitudinal MRI may help monitor disease progression and treatment effects in poorly controlled IGE.
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214647
Open AccessProgressive Changes in Brain Morphology in People With Idiopathic Generalized Epilepsy
Idiopathic generalized epilepsy (IGE) is typically responsive to treatment, yet some people remain poorly controlled despite multiple antiseizure medication trials. Whether this subgroup shows progressive structural brain changes remains uncertain. We aimed to investigate whether people with poorly controlled chronic IGE exhibit progressive morphological brain alterations and how these differ from those in early-stage IGE. This longitudinal case-control neuroimaging study included 2 cohorts: an early-stage IGE group from West China Hospital (Chengdu, China) and a chronic IGE group from the National Hospital for Neurology and Neurosurgery (London, United Kingdom). Participants had a history of generalized seizures and no focal pathology. Matched healthy controls were drawn from 3 public imaging data sets. Participants underwent 2 high-resolution T1-weighted MRI scans at least 12 months apart. Cortical thickness and hippocampal and subcortical volumes were measured on paired scans. Longitudinal changes were assessed using linear mixed-effects models, correcting for age and interscan interval. Structural covariance analysis was conducted to examine inter-regional relationships over time, focusing on thalamo-cortical coupling. Forty-two people with early-stage IGE and 67 with chronic IGE were recruited from 2 separate epilepsy centers, and 109 matched controls were included. The early-stage IGE group showed progressive atrophy limited to the left putamen. Chronic IGE was associated with widespread cortical thinning, primarily in frontal and temporal regions, and thickening in posterior and occipital areas. Subcortical atrophy involves the putamen, thalamus, and pallidum. People with ongoing generalized tonic-clonic seizures showed thickening in the precentral gyrus and additional thinning in the frontal cortex and precuneus. Photosensitive IGE was associated with thickening in the lingual gyrus and occipital cortex. Valproate use was associated with attenuated structural changes in motor, visual, and subcortical regions. Increased structural covariance was observed between the left thalamus and left lingual gyrus in chronic IGE. Chronic IGE, particularly with persistent generalized tonic-clonic seizures or photosensitivity, is associated with more extensive progressive brain changes compared with matched controls. Valproate may have a protective association with these structural changes, although further validation is needed. Longitudinal MRI may help monitor disease progression and treatment effects in poorly controlled IGE.
- Top Cited Papers
- 27 January 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (2) , e214486
Development and International Validation of a Novel Imaging-Based Risk Score (IsCHEMiA) for the Prediction of Poststroke Epilepsy
Stroke is one of the most common causes of adult-onset epilepsy. We aimed to develop a model to predict poststroke epilepsy (PSE) after a first-ever ischemic stroke, incorporating neuroimaging features of incident stroke. We analyzed clinical and neuroimaging features of patients with first-ever acute ischemic stroke consecutively admitted to Massachusetts General Hospital, United States. We performed competing risk regression with all-cause mortality as a competing event and derived the final multivariable model using backward stepwise elimination by the Akaike Information Criterion. We externally validated the model in 3 international cohorts in Hong Kong (Queen Mary Hospital [HK-QMH], Ruttonjee Hospital [HK-RH]) and Japan (National Cerebral and Cardiovascular Center) by discrimination and calibration and compared its performance with the SeLECT and SeLECT2.0 scores. We included a final derivative cohort of 1,436 patients with a mean age of 67.4 years and a slight male predominance (54.7%), along with a total of 2,534 patients in the validation cohorts. PSE, defined as the occurrence or recurrence of unprovoked seizure >7 days after stroke, occurred in 5.5% of the overall study population. Six variables (infarct size [Is], cortical involvement [C], hemorrhagic transformation [H], early seizures [E], MCA involvement [Mi], and age younger than 65 [A]) were independent predictors included in the final model and formed the IsCHEMiA score. Model discrimination was consistent across all cohorts, with c-statistics of 0.870 (United States), 0.852 (HK-QMH), 0.857 (HK-RH), and 0.826 (Japan). The model was well calibrated at 1 and 3 years after stroke in the overall validation cohort. The IsCHEMiA score improved the prediction of PSE compared with SeLECT in all cohorts and the overall study population (c-statistic 0.848 vs 0.782, z = 5.170, p < 0.0001). For example, an IsCHEMiA score of 3 predicts a low risk of PSE at 1 year (2%) and 5 years (6%) while an IsCHEMiA score ≥8 predicts a high risk at 1 year (67%) and 5 years (78%). The IsCHEMiA score is an improved and readily applicable predictive model developed and validated using international stroke cohorts in the modern era of reperfusion therapies. It serves as a foundation for personalized management and may guide future clinical trials on antiepileptogenic therapies in acute ischemic stroke.
- 27 January 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (2) , e214486
Top Cited PapersDevelopment and International Validation of a Novel Imaging-Based Risk Score (IsCHEMiA) for the Prediction of Poststroke Epilepsy
Stroke is one of the most common causes of adult-onset epilepsy. We aimed to develop a model to predict poststroke epilepsy (PSE) after a first-ever ischemic stroke, incorporating neuroimaging features of incident stroke. We analyzed clinical and neuroimaging features of patients with first-ever acute ischemic stroke consecutively admitted to Massachusetts General Hospital, United States. We performed competing risk regression with all-cause mortality as a competing event and derived the final multivariable model using backward stepwise elimination by the Akaike Information Criterion. We externally validated the model in 3 international cohorts in Hong Kong (Queen Mary Hospital [HK-QMH], Ruttonjee Hospital [HK-RH]) and Japan (National Cerebral and Cardiovascular Center) by discrimination and calibration and compared its performance with the SeLECT and SeLECT2.0 scores. We included a final derivative cohort of 1,436 patients with a mean age of 67.4 years and a slight male predominance (54.7%), along with a total of 2,534 patients in the validation cohorts. PSE, defined as the occurrence or recurrence of unprovoked seizure >7 days after stroke, occurred in 5.5% of the overall study population. Six variables (infarct size [Is], cortical involvement [C], hemorrhagic transformation [H], early seizures [E], MCA involvement [Mi], and age younger than 65 [A]) were independent predictors included in the final model and formed the IsCHEMiA score. Model discrimination was consistent across all cohorts, with c-statistics of 0.870 (United States), 0.852 (HK-QMH), 0.857 (HK-RH), and 0.826 (Japan). The model was well calibrated at 1 and 3 years after stroke in the overall validation cohort. The IsCHEMiA score improved the prediction of PSE compared with SeLECT in all cohorts and the overall study population (c-statistic 0.848 vs 0.782, z = 5.170, p < 0.0001). For example, an IsCHEMiA score of 3 predicts a low risk of PSE at 1 year (2%) and 5 years (6%) while an IsCHEMiA score ≥8 predicts a high risk at 1 year (67%) and 5 years (78%). The IsCHEMiA score is an improved and readily applicable predictive model developed and validated using international stroke cohorts in the modern era of reperfusion therapies. It serves as a foundation for personalized management and may guide future clinical trials on antiepileptogenic therapies in acute ischemic stroke.
- Open Access
- 30 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Prevalence of Frailty in Community-Dwelling Adults Aged 18–99 Years: Design and Demographics of the Osaka-Settsu Prospective Cohort Study for Health, Nutrition and Well-being (Preprint)
BACKGROUND Frailty is defined as increased vulnerability to stress. Although frailty is typically associated with older age, it can also affect younger population. In 2024, we launched the Osaka-Settsu Study in Japan. This population-based prospective study aimed to identify the risk factors for lifestyle-related diseases and care given and contribute to precision health care. OBJECTIVE This cohort profile paper describes the study design, the demographics of the participants, and the prevalence of frailty. METHODS A self-administered questionnaire survey was mailed to registered residents aged ≥ 18 years in Settsu City from February to June 2024. The survey asked the participants about physical activity, nutritional status, well-being, and frailty. The participants will be followed up for the incidence of lifestyle-related diseases, need for support/long-term care certification, emergency transportation, and migration. RESULTS Of the 71,680 self-administered questionnaires distributed, 13,282 were completed. The mean age (standard deviation) were 62.1 (17.6) and 60.7 (18.4) years for females and males, respectively. The proportion of robust, prefrail, and frail were 18.5%, 65.5%, and 16.0% in females and, 18.7%, 63.8%, and 17.5% in males, respectively, based on the criteria of the Fried index. The prevalences of frailty in both female and male was 10% across all age groups. CONCLUSIONS Frailty is prevalent even in younger adults. This study is planned to collect information on vital status and conducted follow-up surveys to identify the predictors of functional decline across the course of life. This study provides valuable evidence for the development of strategies to extend a healthy lifespan.
- 30 December 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessPrevalence of Frailty in Community-Dwelling Adults Aged 18–99 Years: Design and Demographics of the Osaka-Settsu Prospective Cohort Study for Health, Nutrition and Well-being (Preprint)
BACKGROUND Frailty is defined as increased vulnerability to stress. Although frailty is typically associated with older age, it can also affect younger population. In 2024, we launched the Osaka-Settsu Study in Japan. This population-based prospective study aimed to identify the risk factors for lifestyle-related diseases and care given and contribute to precision health care. OBJECTIVE This cohort profile paper describes the study design, the demographics of the participants, and the prevalence of frailty. METHODS A self-administered questionnaire survey was mailed to registered residents aged ≥ 18 years in Settsu City from February to June 2024. The survey asked the participants about physical activity, nutritional status, well-being, and frailty. The participants will be followed up for the incidence of lifestyle-related diseases, need for support/long-term care certification, emergency transportation, and migration. RESULTS Of the 71,680 self-administered questionnaires distributed, 13,282 were completed. The mean age (standard deviation) were 62.1 (17.6) and 60.7 (18.4) years for females and males, respectively. The proportion of robust, prefrail, and frail were 18.5%, 65.5%, and 16.0% in females and, 18.7%, 63.8%, and 17.5% in males, respectively, based on the criteria of the Fried index. The prevalences of frailty in both female and male was 10% across all age groups. CONCLUSIONS Frailty is prevalent even in younger adults. This study is planned to collect information on vital status and conducted follow-up surveys to identify the predictors of functional decline across the course of life. This study provides valuable evidence for the development of strategies to extend a healthy lifespan.
- Top Cited PapersOpen Access
- 1 July 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (7) , 1748-1757
Association of the Timing and Type of Acute Symptomatic Seizures With Poststroke Epilepsy and Mortality
BACKGROUND: Acute symptomatic seizures (ASyS) increase the risk of epilepsy and mortality after a stroke. The impact of the timing and type of ASyS remains unclear. METHODS: This multicenter cohort study included data from 9 centers between 2002 and 2018, with a final analysis in February 2024. The study included 4552 adults (2005 female; median age, 73 years) with ischemic stroke and no seizure history. Seizures were classified using International League Against Epilepsy definitions. We examined ASyS occurring within 7 days after stroke. The main outcomes were all-cause mortality and epilepsy. Validation of the updated SeLECT score (SeLECT-ASyS) was performed in 3 independent cohorts (Switzerland, Argentina, and Japan) collected between 2012 and 2024, including 74 adults with ASyS. RESULTS: The 10-year risk of poststroke epilepsy ranged from 41% to 94%, and mortality from 36% to 100%, depending on ASyS type and timing. ASyS on stroke onset day had a higher epilepsy risk (adjusted hazard ratio [aHR], 2.3 [95% CI, 1.3–4.0]; P =0.003) compared with later ASyS. Status epilepticus had the highest epilepsy risk (aHR, 9.6 [95% CI, 3.5–26.7]; P P P =0.004) and status epilepticus (aHR, 14.2 [95% CI, 3.5–58.8]; P P =0.02) and in the validation cohort (0.70 versus 0.50; P =0.18). CONCLUSIONS: ASyS timing and type significantly affect epilepsy and mortality risk after stroke, improving epilepsy prediction and guiding patient counseling.
- 1 July 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (7) , 1748-1757
Top Cited PapersOpen AccessAssociation of the Timing and Type of Acute Symptomatic Seizures With Poststroke Epilepsy and Mortality
BACKGROUND: Acute symptomatic seizures (ASyS) increase the risk of epilepsy and mortality after a stroke. The impact of the timing and type of ASyS remains unclear. METHODS: This multicenter cohort study included data from 9 centers between 2002 and 2018, with a final analysis in February 2024. The study included 4552 adults (2005 female; median age, 73 years) with ischemic stroke and no seizure history. Seizures were classified using International League Against Epilepsy definitions. We examined ASyS occurring within 7 days after stroke. The main outcomes were all-cause mortality and epilepsy. Validation of the updated SeLECT score (SeLECT-ASyS) was performed in 3 independent cohorts (Switzerland, Argentina, and Japan) collected between 2012 and 2024, including 74 adults with ASyS. RESULTS: The 10-year risk of poststroke epilepsy ranged from 41% to 94%, and mortality from 36% to 100%, depending on ASyS type and timing. ASyS on stroke onset day had a higher epilepsy risk (adjusted hazard ratio [aHR], 2.3 [95% CI, 1.3–4.0]; P =0.003) compared with later ASyS. Status epilepticus had the highest epilepsy risk (aHR, 9.6 [95% CI, 3.5–26.7]; P P P =0.004) and status epilepticus (aHR, 14.2 [95% CI, 3.5–58.8]; P P =0.02) and in the validation cohort (0.70 versus 0.50; P =0.18). CONCLUSIONS: ASyS timing and type significantly affect epilepsy and mortality risk after stroke, improving epilepsy prediction and guiding patient counseling.
- Open Access
Association of the timing and type of acute symptomatic seizures with post-stroke epilepsy and mortality
Background Acute symptomatic seizures (ASyS) increase the risk of epilepsy and mortality after a stroke. The impact of the timing and type of ASyS remains unclear. Methods This multicenter cohort study included data from nine centers between 2002 and 2018, with final analysis in February 2024. The study included 4,552 adults (2,005 female; median age 73 years) with ischemic stroke and no seizure history. We examined ASyS occurring within seven days after stroke. Main outcomes were all-cause mortality and epilepsy. Validation in three separate cohorts included 74 adults with ASyS. Results The ten-year risk of post-stroke epilepsy ranged from 41% to 94%, and mortality from 36% to 100%, depending on ASyS type and timing. ASyS on stroke onset day had a higher epilepsy risk (aHR 2.3, 95% CI 1.3-4.0, p=0.003) compared to later ASyS. Status epilepticus had the highest epilepsy risk (aHR 9.6, 95% CI 3.5-26.7, pConclusions ASyS timing and type significantly affect epilepsy and mortality risk after stroke, improving epilepsy prediction and guiding patient counseling.
Open AccessAssociation of the timing and type of acute symptomatic seizures with post-stroke epilepsy and mortality
Background Acute symptomatic seizures (ASyS) increase the risk of epilepsy and mortality after a stroke. The impact of the timing and type of ASyS remains unclear. Methods This multicenter cohort study included data from nine centers between 2002 and 2018, with final analysis in February 2024. The study included 4,552 adults (2,005 female; median age 73 years) with ischemic stroke and no seizure history. We examined ASyS occurring within seven days after stroke. Main outcomes were all-cause mortality and epilepsy. Validation in three separate cohorts included 74 adults with ASyS. Results The ten-year risk of post-stroke epilepsy ranged from 41% to 94%, and mortality from 36% to 100%, depending on ASyS type and timing. ASyS on stroke onset day had a higher epilepsy risk (aHR 2.3, 95% CI 1.3-4.0, p=0.003) compared to later ASyS. Status epilepticus had the highest epilepsy risk (aHR 9.6, 95% CI 3.5-26.7, pConclusions ASyS timing and type significantly affect epilepsy and mortality risk after stroke, improving epilepsy prediction and guiding patient counseling.
- Top Cited PapersOpen Access
- 11 June 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (11) , e209450
Pathophysiology, Diagnosis, Prognosis, and Prevention of Poststroke Epilepsy
Poststroke epilepsy (PSE) is associated with higher mortality and poor functional and cognitive outcomes in patients with stroke. With the remarkable development of acute stroke treatment, there is a growing number of survivors with PSE. Although approximately 10% of patients with stroke develop PSE, given the significant burden of stroke worldwide, PSE is a significant problem in stroke survivors. Therefore, the attention of health policymakers and significant funding are required to promote PSE prevention research. The current PSE definition includes unprovoked seizures occurring more than 7 days after stroke onset, given the high recurrence risks of seizures. However, the pathologic cascade of stroke is not uniform, indicating the need for a tissue-based approach rather than a time-based one to distinguish early seizures from late seizures. EEG is a commonly used tool in the diagnostic work-up of PSE. EEG findings during the acute phase of stroke can potentially stratify the risk of subsequent seizures and predict the development of poststroke epileptogenesis. Recent reports suggest that cortical superficial siderosis, which may be involved in epileptogenesis, is a promising marker for PSE. By incorporating such markers, future risk-scoring models could guide treatment strategies, particularly for the primary prophylaxis of PSE. To date, drugs that prevent poststroke epileptogenesis are lacking. The primary challenge involves the substantial cost burden due to the difficulty of reliably enrolling patients who develop PSE. There is, therefore, a critical need to determine reliable biomarkers for PSE. The goal is to be able to use them for trial enrichment and as a surrogate outcome measure for epileptogenesis. Moreover, seizure prophylaxis is essential to prevent functional and cognitive decline in stroke survivors. Further elucidation of factors that contribute to poststroke epileptogenesis is eagerly awaited. Meanwhile, the regimen of antiseizure medications should be based on individual cardiovascular risk, psychosomatic comorbidities, and concomitant medications. This review summarizes the current understanding of poststroke epileptogenesis, its risks, prognostic models, prophylaxis, and strategies for secondary prevention of seizures and suggests strategies to advance research on PSE.
- 11 June 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (11) , e209450
Top Cited PapersOpen AccessPathophysiology, Diagnosis, Prognosis, and Prevention of Poststroke Epilepsy
Poststroke epilepsy (PSE) is associated with higher mortality and poor functional and cognitive outcomes in patients with stroke. With the remarkable development of acute stroke treatment, there is a growing number of survivors with PSE. Although approximately 10% of patients with stroke develop PSE, given the significant burden of stroke worldwide, PSE is a significant problem in stroke survivors. Therefore, the attention of health policymakers and significant funding are required to promote PSE prevention research. The current PSE definition includes unprovoked seizures occurring more than 7 days after stroke onset, given the high recurrence risks of seizures. However, the pathologic cascade of stroke is not uniform, indicating the need for a tissue-based approach rather than a time-based one to distinguish early seizures from late seizures. EEG is a commonly used tool in the diagnostic work-up of PSE. EEG findings during the acute phase of stroke can potentially stratify the risk of subsequent seizures and predict the development of poststroke epileptogenesis. Recent reports suggest that cortical superficial siderosis, which may be involved in epileptogenesis, is a promising marker for PSE. By incorporating such markers, future risk-scoring models could guide treatment strategies, particularly for the primary prophylaxis of PSE. To date, drugs that prevent poststroke epileptogenesis are lacking. The primary challenge involves the substantial cost burden due to the difficulty of reliably enrolling patients who develop PSE. There is, therefore, a critical need to determine reliable biomarkers for PSE. The goal is to be able to use them for trial enrichment and as a surrogate outcome measure for epileptogenesis. Moreover, seizure prophylaxis is essential to prevent functional and cognitive decline in stroke survivors. Further elucidation of factors that contribute to poststroke epileptogenesis is eagerly awaited. Meanwhile, the regimen of antiseizure medications should be based on individual cardiovascular risk, psychosomatic comorbidities, and concomitant medications. This review summarizes the current understanding of poststroke epileptogenesis, its risks, prognostic models, prophylaxis, and strategies for secondary prevention of seizures and suggests strategies to advance research on PSE.
Periodic discharges plus fast activity on electroencephalogram predict worse outcomes in poststroke epilepsy
Objective: Postseizure functional decline is a concern in poststroke epilepsy (PSE). However, data on electroencephalogram (EEG) markers associated with functional decline are scarce. Thus, we investigated whether periodic discharges (PDs) and their specific characteristics are associated with functional decline in patients with PSE.Methods: In this observational study, patients admitted with seizures of PSE and who had scalp EEGs were included. The association between the presence or absence of PDs and postseizure short‐term functional decline lasting 7 days after admission was investigated. In patients with PD, EEG markers were explored for risk stratification of short‐term functional decline, according to the American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology. The association between EEG markers and imaging findings and long‐term functional decline at discharge and 6 months after discharge, defined as an increase in the modified Rankin Scale score compared with the baseline, was evaluated.Results: In this study, 307 patients with PSE (median age = 75 years, range = 35–97 years, 64% males; hemorrhagic stroke, 47%) were enrolled. Compared with 247 patients without PDs, 60 patients with PDs were more likely to have short‐term functional decline (12 [20%] vs. 8 [3.2%], p < .001), with an adjusted odds ratio (OR) of 4.26 (95% confidence interval [CI] = 1.44–12.6, p = .009). Patients with superimposed fast‐activity PDs (PDs+F) had significantly more localized (rather than widespread) lesions (87% vs. 58%, p = .003), prolonged hyperperfusion (100% vs. 62%, p = .023), and a significantly higher risk of short‐term functional decline than those with PDs without fast activity (adjusted OR = 22.0, 95% CI = 1.87–259.4, p = .014). Six months after discharge, PDs+F were significantly associated with long‐term functional decline (adjusted OR = 4.21, 95% CI = 1.27–13.88, p = .018).Significance: In PSE, PDs+F are associated with sustained neuronal excitation and hyperperfusion, which may be a predictor of postseizure short‐ and long‐term functional decline.
Periodic discharges plus fast activity on electroencephalogram predict worse outcomes in poststroke epilepsy
Objective: Postseizure functional decline is a concern in poststroke epilepsy (PSE). However, data on electroencephalogram (EEG) markers associated with functional decline are scarce. Thus, we investigated whether periodic discharges (PDs) and their specific characteristics are associated with functional decline in patients with PSE.Methods: In this observational study, patients admitted with seizures of PSE and who had scalp EEGs were included. The association between the presence or absence of PDs and postseizure short‐term functional decline lasting 7 days after admission was investigated. In patients with PD, EEG markers were explored for risk stratification of short‐term functional decline, according to the American Clinical Neurophysiology Society's Standardized Critical Care EEG Terminology. The association between EEG markers and imaging findings and long‐term functional decline at discharge and 6 months after discharge, defined as an increase in the modified Rankin Scale score compared with the baseline, was evaluated.Results: In this study, 307 patients with PSE (median age = 75 years, range = 35–97 years, 64% males; hemorrhagic stroke, 47%) were enrolled. Compared with 247 patients without PDs, 60 patients with PDs were more likely to have short‐term functional decline (12 [20%] vs. 8 [3.2%], p < .001), with an adjusted odds ratio (OR) of 4.26 (95% confidence interval [CI] = 1.44–12.6, p = .009). Patients with superimposed fast‐activity PDs (PDs+F) had significantly more localized (rather than widespread) lesions (87% vs. 58%, p = .003), prolonged hyperperfusion (100% vs. 62%, p = .023), and a significantly higher risk of short‐term functional decline than those with PDs without fast activity (adjusted OR = 22.0, 95% CI = 1.87–259.4, p = .014). Six months after discharge, PDs+F were significantly associated with long‐term functional decline (adjusted OR = 4.21, 95% CI = 1.27–13.88, p = .018).Significance: In PSE, PDs+F are associated with sustained neuronal excitation and hyperperfusion, which may be a predictor of postseizure short‐ and long‐term functional decline.
- 10 June 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (8) , 1454-1461
Pre-existing sarcopenia and swallowing outcomes in acute stroke patients
- 10 June 2023
- Published by Elsevier in Clinical Nutrition
- Vol. 42 (8) , 1454-1461
Pre-existing sarcopenia and swallowing outcomes in acute stroke patients